| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Estrogen receptors (ERα and ERβ). Iriflophenone stimulates the proliferation of MCF-7 and T-47D human breast cancer cells, both of which are estrogen receptor-positive cell lines. This proliferative activity suggests that iriflophenone may act as an estrogen receptor agonist or modulator. The compound's mechanism likely involves binding to estrogen receptors and activating estrogen-responsive gene expression, leading to cell cycle progression and proliferation. The compound also exhibits antioxidant activity through free radical scavenging and may have anti-inflammatory effects.
|
|---|---|
| ln Vitro |
Iriflophenone stimulates the proliferation of MCF-7 and T-47D human breast cancer cells. The compound's proliferative activity on estrogen receptor-positive breast cancer cells suggests estrogenic activity. DPPH radical scavenging activity has been used to evaluate the antioxidant capacity of iriflophenone-containing extracts. The compound displays significant potential as an effective antioxidant agent and is useful for its anti-inflammatory and anticancer effects in laboratory experiments. Its specific in vitro activities depend on the concentrations tested and the assay systems used.
|
| ln Vivo |
In vivo studies of iriflophenone are limited. As a phenolic compound with estrogenic activity, it may have potential effects on estrogen-sensitive tissues and could be evaluated in animal models of breast cancer or estrogen-related conditions. Its antioxidant and anti-inflammatory properties suggest potential benefits in oxidative stress and inflammation models. Further studies are needed to characterize its specific in vivo pharmacokinetic and pharmacodynamic properties, as well as its efficacy and safety profile.
|
| Enzyme Assay |
Non-cell-based assays for iriflophenone include estrogen receptor binding assays using radiolabeled estradiol to assess affinity for ERα and ERβ. Antioxidant activity is assessed using DPPH radical scavenging, ABTS, and FRAP assays. Anti-inflammatory activity can be measured by inhibition of COX-2 or cytokine production in enzyme assays. Standard analytical methods including HPLC, NMR, and mass spectrometry are used for compound characterization and purity assessment. Physicochemical properties such as solubility and stability are determined using standard protocols.
|
| Cell Assay |
Cell-based assays for iriflophenone use MCF-7 and T-47D human breast cancer cells to assess its proliferative activity. Cells are cultured in estrogen-free medium and treated with iriflophenone at various concentrations. Cell proliferation is measured using MTT, BrdU incorporation, or cell counting assays. Estrogen receptor activation is assessed using reporter gene assays with an estrogen response element (ERE)-luciferase construct. For antioxidant studies, cells are exposed to oxidative stress inducers and treated with the compound, and intracellular ROS levels are measured using fluorescent probes.
|
| Animal Protocol |
In vivo studies of iriflophenone are limited. Based on its proliferative activity on estrogen receptor-positive breast cancer cells, potential animal models include: ovariectomized rat models for estrogenic effects; and tumor xenograft models for breast cancer evaluation. Standard protocols for these models involve administration of the compound followed by measurement of relevant endpoints including tumor volume, uterine weight, and histopathological analysis. Further studies are needed to establish the compound's in vivo efficacy and safety.
|
| ADME/Pharmacokinetics |
Iriflophenone has a molecular formula of C₁₃H₁₀O₅ and a molecular weight of 246.22 g/mol. The CAS number is 52591-10-3. The canonical SMILES is O=C(C1=CC=C(O)C=C1)C2=C(O)C=C(O)C=C2O. The compound should be stored as a powder at -20°C or in solvent at -80°C for up to 6 months. It is soluble in DMSO and other organic solvents. Sample solutions are provided at 25 µL, 10 mM. It is intended for research use only.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for iriflophenone are limited. As a phenolic compound with estrogenic activity, it may have effects on hormone-sensitive tissues. The compound stimulates breast cancer cell proliferation, indicating biological activity at certain concentrations. Standard laboratory safety practices should be followed when handling this compound, including the use of personal protective equipment. It is intended for research use only and is not for human consumption.
|
| References |
|
| Additional Infomation |
Reports indicate that iris (Iris potaninii), domestic iris (Iris domestica), and agarwood (Aquilaria sinensis) contain irisone, and relevant data is available for reference.
Iriflophenone is a phenolic compound isolated from Aquilaria sinensis (agarwood) and other medicinal plants. It stimulates the proliferation of MCF-7 and T-47D human breast cancer cells, both of which are estrogen receptor-positive cell lines. This proliferative activity suggests that iriflophenone may act as an estrogen receptor agonist or modulator. The compound displays significant potential as an effective antioxidant agent and is useful for its anti-inflammatory and anticancer effects in laboratory experiments. It is used as a research tool for studying estrogen receptor signaling and breast cancer cell proliferation. It is for research use only. |
| Molecular Formula |
C13H10O5
|
|---|---|
| Molecular Weight |
246.22
|
| Exact Mass |
246.052
|
| CAS # |
52591-10-3
|
| PubChem CID |
11311158
|
| Appearance |
White to yellow solid
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
482.4±33.0 °C at 760 mmHg
|
| Flash Point |
259.6±21.9 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.718
|
| LogP |
3.18
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
18
|
| Complexity |
286
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=CC=C1C(=O)C2=C(C=C(C=C2O)O)O)O
|
| InChi Key |
AOJWDTJDEGSHOA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H10O5/c14-8-3-1-7(2-4-8)13(18)12-10(16)5-9(15)6-11(12)17/h1-6,14-17H
|
| Chemical Name |
(4-hydroxyphenyl)-(2,4,6-trihydroxyphenyl)methanone
|
| Synonyms |
Iriflophenone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 250 mg/mL (1015.35 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0614 mL | 20.3070 mL | 40.6141 mL | |
| 5 mM | 0.8123 mL | 4.0614 mL | 8.1228 mL | |
| 10 mM | 0.4061 mL | 2.0307 mL | 4.0614 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
